Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients

NCT05984615 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05984615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05984615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Evaluation of the Impact of Baseline Metastases on Clinical Outcomes Among BRAF Positive Metastatic Melanoma Patients
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
June 8, 2022
Completion date
August 24, 2022
Enrollment
1,961 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf positive metastatic melanoma